Naurex's Novel Antidepressant GLYX-13 Recognized as One of
Windhover's Top 10 Neuroscience Projects to Watch
From the PharmaLive.com News Archive - Aug. 31, 2010
Naurex today reported that its clinical stage candidate for the
treatment of depression, GLYX-13, and its second-generation NRX-1050
series have been selected for inclusion on Windhover's list of the
"Top 10 Most Interesting Neuroscience Projects to Watch." They were
chosen by a committee that included Windhover Information, the
publishers of IN VIVO and Start-Up, and independent CNS expert Harry
Tracy, president of NI Research and editor of the neuroscience
business analysis journal NeuroInvestment.
www.peoplewho.org